# Rabacfosadine

Source: https://onco.cc/drugs/rabacfosadine/  
OnCo record `rabacfosadine` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rabacfosadine (Tanovea) is an intravenous drip for dogs with lymphoma, conditionally approved by the US Food and Drug Administration in 2016 and fully approved in 2021. It is a medicine for dogs and is not used in people.

## Summary

Tanovea (rabacfosadine for injection) was conditionally approved by the FDA Center for Veterinary Medicine in December 2016 (as Tanovea-CA1) and received full approval on 15 July 2021 under NADA 141-545, sponsored by VetDC, Inc., for the treatment of lymphoma in dogs. The labelled regimen is 1 mg/kg by intravenous infusion every 21 days for up to five doses.

The effectiveness study randomised client-owned dogs with multicentric B-cell or T-cell lymphoma 3:1 to rabacfosadine or saline placebo. Median progression-free survival was 82 days against 21 days (P < 0.0001); in dogs with a complete or partial response it was 151 days. The commonest adverse reactions were diarrhoea, decreased appetite, vomiting, lethargy, weight loss and neutropenia. It is a veterinary medicine and has no human approval.

## Fields

- Kind: Treatment
- Last checked: 2026-11-04
- Also known as: Tanovea; Tanovea-CA1; rabacfosadine for injection
- Tags: veterinary; comparative-oncology
- Brand: Tanovea
- Modality: small molecule (nucleotide analogue)
- Mechanism: A small molecule that mimics the nucleoside guanine; the FDA summary states it preferentially targets rapidly dividing lymphoma cells and interferes with their DNA synthesis, reducing proliferation and causing cell death.

## Sources

- FDA Consumer Update: My Dog Has Cancer: What Do I Need to Know?: https://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know
- FDA Freedom of Information Summary, NADA 141-545 Tanovea (approved 15 July 2021): https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11083

## Connected records

- ideas: [Pet dogs with spontaneous cancer as a bridge before human trials](https://onco.cc/ideas/idea-bio1-comparative-oncology-dogs/)
- journals: [Veterinary and comparative oncology](https://onco.cc/journals/veterinary-and-comparative-oncology/)

---
JSON: https://onco.cc/api/v1/entities/rabacfosadine.json